What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space.

Over a dozen companies have launched programs to immunize cancer patients against mutations in their own tumors, which produce “non-self” peptide antigens akin to those from foreign pathogens. ...